EAM Investors’s Akebia Therapeutics AKBA Stock Holding History

EAM Investors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,454,328	Closed	-$5.29M	–	257
2025 Q2	$5.29M	Sell	1,454,328 -323,583	-18%	-$889K	0.8%	30
2025 Q1	$3.41M	Buy	+1,777,911	New	+$3.63M	0.59%	72
2024 Q2	–	Sell	-428,549	Closed	-$784K	–	247
2024 Q1	$784K	Buy	+428,549	New	+$685K	0.12%	207
2020 Q3	–	Sell	-201,521	Closed	-$2.74M	–	270
2020 Q2	$2.74M	Buy	+201,521	New	+$2.08M	0.61%	35
2018 Q1	–	Sell	-180,503	Closed	-$2.68M	–	285
2017 Q4	$2.68M	Sell	180,503 -54,967	-23%	-$912K	0.48%	71
2017 Q3	$4.63M	Buy	235,470 +12,330	+6%	+$190K	0.62%	37
2017 Q2	$3.21M	Buy	+223,140	New	+$2.83M	0.53%	58
2016 Q1	–	Sell	-380,433	Closed	-$4.92M	–	295
2015 Q4	$4.92M	Buy	380,433 +138,993	+58%	+$1.42M	0.64%	13
2015 Q3	$2.33M	Buy	+241,440	New	+$2.22M	0.37%	122

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

EAM Investors's AKBA Position: Q3 2025 in Review

EAM Investors sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 1,454,328 shares — an estimated $5.29M sold.

EAM Investors first reported a position in AKBA in Q3 2015 and held it in 9 quarters. The position peaked at $5.29M in Q2 2025. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

EAM Investors reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
EAM Investors sold 1,454,328 Akebia Therapeutics shares in Q3 2025, an estimated $5.29M.
EAM Investors first reported a position in Akebia Therapeutics in Q3 2015 and held it in 9 quarters.
EAM Investors's Akebia Therapeutics position peaked at $5.29M in Q2 2025.
177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.